Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Perry H. Dubin"'
Autor:
Henry Roberts, Sameh W Boktor, Kirsten Waller, Zahra S Daar, Joseph A Boscarino, Perry H Dubin, Anil Suryaprasad, Anne C Moorman
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0217455 (2019)
ContextIn Pennsylvania, reporting of viral hepatitis B (HBV) and viral hepatitis C (HCV) infections to CDC has been mandated since 2002. Underreporting of HBV and HCV infections has long been identified as a problem. Few reports have described the ac
Externí odkaz:
https://doaj.org/article/9769ee81688049ec93807260b9d0ebba
Autor:
Santiago Munoz, Michael L. Schilsky, William M. Lee, Timothy M. McCashland, Jeffrey S. Crippin, Linda S. Hynan, A. Obaid, Daniel Ganger, Atif Zaman, Steven Han, Perry H. Dubin, Robert S. Brown, Edwin Harrison, Anne M. Larson, Raymond T. Chung, Andres T. Blei, J. Eileen Hay, Mamta K. Jain, Alastair D. Smith, Brendan M. McGuire, R. Todd Stravitz, Rajender Reddy, Oren K Fix, Robert K. Devine, Tarek Hassanein, Adrian Reuben, S. Shaikh, Natalie Murray, Timothy J. Davern, Lorenzo Rossaro, Iris Liou, Hejun Yuan, Raj Satyanarayana, Robert J. Fontana
Publikováno v:
Journal of Medical Virology. 86:1507-1514
MicroRNA-122 (miR-122) is the foremost liver-related micro-RNA, but its role in the hepatocyte is not fully understood. To evaluate whether circulating levels of miR-122 are elevated in chronic-HCV for a reason other than hepatic injury, we compared
Autor:
Seth N. Sclair, Amelia K Boehme, Paul J. Martin, William M. Lee, Perry H. Dubin, Rene Rico, Emerson Y. Chen
Publikováno v:
Digestive Diseases and Sciences. 60:272-274
To the editor, We read with great interest the research article, ‘‘Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus in a Large Integrated Care Setting’’ by Price et al. [1]. To date, there have bee
Publikováno v:
Stroke. 44
Background: The circumstances for morbidity differ between acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH). The need for Percutaneous Endoscopic Gastrostomy (PEG) tube placement may be associated with further morbidity. This study aims
A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir
Autor:
Seth N. Sclair, Betty Apica, Frank Czul, William M. Lee, Paul J. Martin, Perry H. Dubin, Emerson Y. Chen
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 11(8)
Background & Aims Protease inhibitor triple therapy for hepatitis C virus (HCV) infection (boceprevir or telaprevir with pegylated interferon and ribavirin) has been shown to increase rates of sustained virologic response in phase 3 trials. We invest
Publikováno v:
American Journal of Gastroenterology. 109:S135
Results 196 responses were analyzed (9 GI, 27 FIM, 90 PMS, and 70 CMS). Analysis identified differences in knowledge of HCV curability (p
Publikováno v:
Gastroenterology. 144:S-983
Publikováno v:
Gastroenterology. 144:S-976